Analytical Cytometry Core Shared Resource ABSTRACT To advance our understanding of cancer etiology and to develop improved therapeutic approaches, it is critical for researchers to have the ability to routinely analyze and isolate discrete cell types from complex heterogeneous populations. The Analytical Cytometry Core (ACC) fulfills this vital function for CC members by providing services to define and isolate discrete immune system cells and cancer cells based on cell surface markers, to quantify and isolate cells that express fluorescent markers, and to examine discrete cell growth states. The ACC provides flow cytometry analysis and sorting instrumentation (ten analyzers, four sorters) to support the research goals of the City of Hope Comprehensive Cancer Center (COHCCC). The ACC maintains several analysis instruments (BC Gallios, BC CyAn, BD C6, and two BD Fortessas) that enable varying degrees of parameter detection in the Furth building on the COH main campus. These instruments can be operated either by researchers or by core staff. A small particle analyzer (e.g., exosome and nanoparticle; NanoSight NS300) is also available at this location. Additional analyzers are available throughout the main campus and the City of Hope Biomedical Research Center (BC Gallios, two BD C6, BD Fortessa, and BD Fortessa X-20). Three high-parameter cell sorting instruments (BD Aria sorters), located on the main campus and the City of Hope Biomedical Research Center, are maintained and operated by core staff. An additional simple cell sorter (Bio- Rad S3), located on the main campus, is available for operation by individual researchers. Several additional instruments are on order with scheduled delivery in July 2017: a BD Fortessa X-20, a BD Aria Fusion sorter, and a state-of-the-art high-dimensional cytometer (BD FACSymphony). The core is directed by Dr. Jeremy Stark, a Professor in the Department of Cancer Genetics and Epigenetics, and supported by highly qualified staff that maintain and operate the equipment while also providing training to COHCCC researchers who wish to operate ACC instruments independently. Trained and authorized users have 24/7 access to the instrumentation, and core staff schedules are staggered to allow for an extended workday for core-assisted operation. Oversight is provided by an interdisciplinary faculty Advisory Committee, and user feedback through an annual survey. Over the past five years, the ACC was used by 142 unique investigators, including 94 CC members. Of the 94 CC members, 79 (84%) had peer-reviewed funding. Usage included members from all five Programs. Thus, the ACC provides accessible, cost-effective, and high quality flow cytometry services to support the research of the COHCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-35
Application #
9491624
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-04-20
Budget End
2018-11-30
Support Year
35
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Liu, Liang; Yang, Lin; Yan, Wei et al. (2018) Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clin Cancer Res 24:2370-2382
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Moreira, Dayson; Adamus, Tomasz; Zhao, Xingli et al. (2018) STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin Cancer Res 24:5948-5962
Choi, Audrey H; O'Leary, Michael P; Chaurasiya, Shyambabu et al. (2018) Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer. Surgery 163:336-342
Golfetto, Ottavia; Wakefield, Devin L; Cacao, Eliedonna E et al. (2018) A Platform To Enhance Quantitative Single Molecule Localization Microscopy. J Am Chem Soc 140:12785-12797
Wolfson, Julie A; Richman, Joshua S; Sun, Can-Lan et al. (2018) Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment. Cancer Epidemiol Biomarkers Prev 27:1133-1141
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 1396 publications